Adage Capital Partners GP L.L.C. Cuts Stock Position in Astria Therapeutics, Inc. $ATXS

Adage Capital Partners GP L.L.C. cut its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 17.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 588,200 shares of the biotechnology company's stock after selling 125,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned 1.04% of Astria Therapeutics worth $3,141,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. ADAR1 Capital Management LLC lifted its position in Astria Therapeutics by 605.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after acquiring an additional 550,706 shares in the last quarter. PDT Partners LLC lifted its holdings in shares of Astria Therapeutics by 173.2% during the 1st quarter. PDT Partners LLC now owns 28,707 shares of the biotechnology company's stock valued at $153,000 after buying an additional 18,200 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of Astria Therapeutics by 503.7% during the 1st quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company's stock valued at $493,000 after buying an additional 76,961 shares during the period. DAFNA Capital Management LLC lifted its holdings in shares of Astria Therapeutics by 5.0% during the 1st quarter. DAFNA Capital Management LLC now owns 314,775 shares of the biotechnology company's stock valued at $1,681,000 after buying an additional 15,000 shares during the period. Finally, Jump Financial LLC bought a new position in shares of Astria Therapeutics during the 1st quarter valued at $178,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Trading Down 0.5%

Astria Therapeutics stock traded down $0.04 during trading on Wednesday, reaching $7.49. The company had a trading volume of 460,229 shares, compared to its average volume of 356,758. Astria Therapeutics, Inc. has a 52 week low of $3.56 and a 52 week high of $12.92. The firm's 50-day simple moving average is $6.58 and its 200 day simple moving average is $5.70. The firm has a market capitalization of $422.74 million, a price-to-earnings ratio of -3.73 and a beta of 0.42.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. On average, analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Analysts Set New Price Targets

ATXS has been the topic of several research analyst reports. JMP Securities increased their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a report on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Wednesday, August 13th. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat.com, Astria Therapeutics has a consensus rating of "Buy" and a consensus target price of $29.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.